Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $56 | $53 | $50 | $53 |
| % Growth | 7% | 5.1% | -5.9% | – |
| Cost of Goods Sold | $3 | $4 | $4 | $3 |
| Gross Profit | $53 | $48 | $47 | $51 |
| % Margin | 94.7% | 91.5% | 93% | 95.1% |
| R&D Expenses | $23 | $22 | $36 | $20 |
| G&A Expenses | $0 | $0 | $0 | $37 |
| SG&A Expenses | $60 | $65 | $50 | $39 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $2 | $0 | $5 | $2 |
| Operating Expenses | $85 | $87 | $91 | $61 |
| Operating Income | -$31 | -$39 | -$45 | -$10 |
| % Margin | -55.6% | -73.2% | -89% | -19.3% |
| Other Income/Exp. Net | $3 | $4 | $7 | $4 |
| Pre-Tax Income | -$28 | -$35 | -$37 | -$6 |
| Tax Expense | -$6 | -$8 | -$8 | -$2 |
| Net Income | -$23 | -$27 | -$29 | -$5 |
| % Margin | -40.1% | -51.7% | -58.9% | -9.2% |
| EPS | -0.38 | -0.46 | -0.5 | -0.085 |
| % Growth | 17.4% | 8% | -491.7% | – |
| EPS Diluted | -0.38 | -0.46 | -0.5 | -0.085 |
| Weighted Avg Shares Out | 59 | 59 | 59 | 58 |
| Weighted Avg Shares Out Dil | 59 | 59 | 59 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $2 |
| EBITDA | -$29 | -$33 | -$31 | -$8 |
| % Margin | -52% | -62.5% | -62.2% | -15.6% |